Program
fingolimod
Also written as “Fingolimod”, “FTY720” and “Fingolimod 0.5 mg”.
Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · Renal Insufficiency · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Multiple Sclerosis, Chronic Progressive, led by 4 companies.
Drug pageFingolimod: every studyAll 75 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 502 open or running | phase 4since Sep 7, 2010 | Dec 7, 2004 | none ahead |
| Alembic Pharmaceuticals | 10 open or running | phase 1since Nov 23, 2015 | Nov 23, 2015 | none ahead |
| Asofarma S.A.I. y C.its history only | 10 open or running | phase 1since Nov 27, 2018 | Nov 27, 2018 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Dec 2, 2020 | Dec 2, 2020 | none ahead |
Also a collaborator on its studies: Hikma Pharmaceuticals, Zenith Technology and Tanabe Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alembic Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2015First study: phase 1 study in BioequivalenceFirst studyNCT05145621 · 26 enrolled · Canada
TargetBeta
“The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, ”NCIt, by rule
“Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent”ChEMBL 37, by rule
Studies
The one study Alembic Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05145621Bioequivalence · Canada | 1 | Completed | Jan 15, 2016 | 26 |
How it is read
Names in the registry
- “Fingolimod”, 22 entries
- “FTY720”, 16 entries
- “Fingolimod 0.5 mg”, 4 entries
- “fingolimod”, 4 entries
- “Fingolimod 1.25 mg”, 3 entries
Conditions, from the studies’ own filings
- Multiple Sclerosis, 20 studies
- Multiple Sclerosis, Relapsing-Remitting, 15 studies
- Renal Insufficiency, 1 study
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 study
- Multiple Sclerosis, Chronic Progressive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.